ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Birmingham, AL, USA:

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Veliparib and Lapatinib, given to participants with metastatic triple negative breast cancer that have undergone ...

Active, not recruiting
Metastatic Triple Negative Breast Cancer
Drug: Combination of Veliparib + Lapatinib
The University of Alabama at Birmingham
The University of Alabama at Birmingham

Birmingham, Alabama, United States

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)

This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms bas...

Active, not recruiting
Breast Cancer
Triple Negative Breast Cancer
Drug: Inavolisib
Drug: Talazoparib

Phase 2

Bryan Schneider, MD

Birmingham, Alabama, United States and 12 other locations

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. -...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Pembrolizumab
Drug: ladiratuzumab vedotin

Phase 1, Phase 2

Seagen
Seagen

Birmingham, Alabama, United States and 49 other locations

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)

avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage I...

Enrolling
Stage IIIA Breast Cancer
Recurrent Breast Carcinoma
Biological: Utomilumab
Biological: Anti-OX40 Antibody PF-04518600

Phase 2

Hope Rugo, MD

Birmingham, Alabama, United States and 11 other locations

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Birmingham, Alabama, United States of America and 165 other locations

A Study of PF-06873600 in People With Cancer

or metastatic (spread to other parts of the body); triple negative breast cancer; epithelial ovarian cancer...

Active, not recruiting
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Drug: Endocrine Therapy 1
Drug: PF-06873600

Phase 2

Pfizer
Pfizer

Birmingham, Alabama, United States and 55 other locations

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple...

Active, not recruiting
Metastatic Triple Negative Breast Cancer
Drug: Olaparib Continuous (28-Day cycle) 300 mg BD.
Drug: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).

Phase 2

AstraZeneca
AstraZeneca

Birmingham, Alabama, United States and 140 other locations

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It wi ...

Enrolling
Ovarian Neoplasms
Gastric Cancer
Drug: pembrolizumab
Drug: PF-08046054

Phase 1

Seagen
Seagen

Birmingham, Alabama, United States and 23 other locations

A Study of Enzalutamide, Enzalutamide in Combination with Mifepristone, or Chemotherapy in People with Metastatic Breast Cancer

in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estro ...

Enrolling
Metastatic Breast Cancer
Drug: Mifepristone
Drug: Enzalutamide

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Birmingham, Alabama, United States and 11 other locations

NM32-2668 in Adult Patients with Selected Advanced Solid Tumors

tumors....

Enrolling
Endometrial Cancer
Triple Negative Breast Cancer
Biological: NM32-2668

Phase 1

Numab Therapeutics

Birmingham, Alabama, United States and 7 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems